Can we predict which RA pts will have secondary failure to TNFi in advance? B-cell activating factor (BAFF) may play a role, and in age >54, pre-TNFi BAFF levels predict anti-drug Ab. A potential step toward better drug survival? La Paz, Madrid THU0170 #EULAR2020 @RheumNow https://t.co/NRQHO2cVuf

#EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal. Results: 63% flared who had TNFi w/drawn vs. 5% when TNFi continued @RheumNow https://t.co/SsR1vUGbOe

Do certain TNFi get more affected by obesity in RA? I have colleagues convinced infliximab is better for obese pts (weight-based dosing). It actually seems obese RA pts might do as well as other RA pts w etanercept, but not w infliximab! @DrMiniDey OP0220 #EULAR2020 @RheumNow https://t.co/EsaLTqINpd

And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L

Another Italian COVID-19 dermatology report: 1,193 skin psoriasis patients on TNFi, IL17,IL23,IL12/23 & apremilast: 22 patients infected, of those 5 hospitalised, none died https://t.co/HpN908qsHd

• https://onlinelibrary.wiley.com/doi/full/10.1111/dth.13475

#EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status. @RheumNow https://t.co/Hkv6T7pl9f

Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6

• E-CONGRESS

This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4

COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396 https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K

• E-CONGRESS

10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3

• EULAR Abstract Archive

Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI

• https://twitter.com/pkiely500/status/1268871993539072001

Certolizumab Pegol: A Safe And Efficient Treatment In Patients With Uveitis During Pregnancy: Conclusion: CZP seems to be effective and safe in female patients with uveitis during pregnancy and neonates. Abstract AB1055 #EULAR2020 @RheumNow https://t.co/MzeZKBawTg